Research location
Klerksdorp
North West, South Africa
Advertisement
Research activity in Klerksdorp
North West, South AfricaCureCurrent currently publishes aggregate city-level research activity for this location: 31 trials and 42 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Klerksdorp
31 linked trials · page 1 of 1HomeLink2: Reducing Posthospitalization Mortality Through Structured Home Care and Nutritional SupportNCT07102745 · 2025-07-24 · 1 site observation
RECRUITING
Remote Ischaemic Conditioning in STEMI Patients in AFRICANCT04813159 · 2022-01-12 · 1 site observation
RECRUITING
Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South AfricaNCT05539989 · 2026-12-31 · 1 site observation
WITHDRAWN
A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + AlumNCT06267872 · 2024-10-07 · 1 site observation
WITHDRAWN
Pausing Antiretroviral Treatment Under Structured EvaluationNCT06031272 · 2024-05-28 · 1 site observation
COMPLETED
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIVNCT05122026 · 2024-01-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsNCT05118490 · 2023-07-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)NCT05122767 · 2023-05-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African WomenNCT05746065 · 2022-08-01 · 1 site observation
COMPLETED
Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults.NCT05515042 · 2022-07-25 · 1 site observation
UNKNOWN
Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of ConcernNCT05168813 · 2021-12-01 · 1 site observation
COMPLETED
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)NCT04644029 · 2021-02-24 · 1 site observation
TERMINATED
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIVNCT04556981 · 2020-11-17 · 1 site observation
COMPLETED
Catalysing the Containment of COVID-19NCT04523090 · 2020-08-27 · 1 site observation
TERMINATED
Home Link: Post Hospital Care to Reduce HIV Mortality in South AfricaNCT04436289 · 2020-07-01 · 1 site observation
COMPLETED
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in Children With MDR-TB With and Without HIVNCT03141060 · 2019-02-18 · 1 site observation
COMPLETED
Study to Evaluate H56:IC31 in Preventing Rate of TB RecurrenceNCT03512249 · 2019-01-31 · 1 site observation
COMPLETED
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIVNCT02906007 · 2017-09-21 · 1 site observation
COMPLETED
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected AdultsNCT02915016 · 2016-12-07 · 1 site observation
COMPLETED
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South AfricaNCT02968849 · 2016-10-26 · 1 site observation
COMPLETED
Safety and Immune Response to a Clade C DNA HIV VaccineNCT02997969 · 2016-06-21 · 1 site observation
COMPLETED
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in WomenNCT02568215 · 2016-05-01 · 1 site observation
COMPLETED
Collaborative Care for the Detection and Management of Depression Among Adults Receiving Antiretroviral Therapy in South AfricaNCT02407691 · 2015-04-01 · 1 site observation
COMPLETED
Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South AfricaNCT02119130 · 2014-11-01 · 10 site observations
COMPLETED
A Smoking Cessation Trial in HIV-infected Patients in South AfricaNCT01484340 · 2014-03-28 · 3 site observations
COMPLETED
Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate CancerNCT01656161 · 2012-07-01 · 1 site observation
COMPLETED
Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy AdultsNCT01418235 · 2011-12-19 · 1 site observation
COMPLETED
Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated AdultsNCT01017536 · 2009-12-01 · 1 site observation
COMPLETED
An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine TrialsNCT03337906 · 2008-07-11 · 1 site observation
COMPLETED
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast CancerNCT00065325 · 2003-08-01 · 1 site observation
COMPLETED
A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness TrialsNCT00029913 · 2002-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.